OSIRIS THERAPEUTICS, INC.
OSIRIS THERAPEUTICS, INC. (OSIR): 5 pipeline candidates · ~20 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.9 months
D/E 0.29 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for OSIRIS THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$16.4M
Quarterly Burn
$5.7M
Runway
19.9 mo
Revenue
$40.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| bio4 | Approved |
| cartiform | Approved |
| grafix | Approved |
| grafixpl prime | Approved |
| stravix | Approved |
Frequently asked questions
How many drug candidates are in OSIRIS THERAPEUTICS, INC.'s pipeline?
OSIRIS THERAPEUTICS, INC. (OSIR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OSIRIS THERAPEUTICS, INC.'s lead drug candidate?
OSIRIS THERAPEUTICS, INC.'s most advanced tracked candidate is bio4 (Approved) for Bone repair and regeneration.
What is OSIRIS THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OSIRIS THERAPEUTICS, INC. has approximately 19.9 months of cash runway.
Who is the CEO of OSIRIS THERAPEUTICS, INC.?
Jason Keefer is the chief executive officer of OSIRIS THERAPEUTICS, INC. (OSIR).
Get the full picture on OSIRIS THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.